Conjugate vaccines are manufactured by linking an antigen to a protein molecule. It comprises of a polysaccharide antigen joined a carrier protein. The grouping of an antigen with protein forms a substance which is identifiable to the blood cells in the humanoid blood, resulting in a robust immune response. It is used for immunizing children against microorganism that has polysaccharide capsular. Conjugate vaccines provide enduring immunity. Some of the major examples of the products are shingles, Hib (Haemophilus influenza type b) disease, hepatitis B, Pneumococcal Conjugate Vaccine (PCV) and whooping cough.
In U.K., the main brand of PCV is called prevenar 13 which is recommended for all age’s people with some health restrictions who are at greater risk of obstacles such as diabetes, chronic lung conditions, cerebrospinal fluid leaks, chronic liver disease (heart disease & kidney disease), immunosuppression and cochlear implants etc.
According to study, “Europe Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Europe conjugate vaccine market are Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer Inc., CSL Limited.
The use of conjugate vaccine can be used for influenza, hepatitis, HPV (human papillomavirus), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, herpes zoster, and other disease indications. Moreover, based on the route of administration, the market is segmented into oral administration, subcutaneous administration and intramuscular administration and many others.
Some of the major benefits of conjugate vaccinations are the cost-effectiveness; elicit long term protections, high efficacy against vaccines and high serotype coverage etc. Some of the disadvantages are complex & complicated preparation loss of immunogenicity etc. Moreover, these vaccinations may cause side effects such as tenderness, loss of appetite, redness, allergic reaction, slight fever and swelling at the site of the shot.
The European Centre for Disease Prevention and Control (ECDC) is a government agency formed with an objective to support infective diseases. Agency also assists by providing toolkits and immunization program for managers & public health specialists to efforts in addressing vaccine consumption awareness. In addition, the National Infant Immunization Program (NIIP) is a government synchronized authority, which is mainly help in preventing vaccine avoidable diseases in children.
The market of Europe conjugate vaccine is mainly driven by increasing prominence on &availability of resources for research and development (R&D), followed by raising awareness about the convenience of a higher number of vaccines, modernization of healthcare infrastructure, growing disposable income, rising prevalence of infectious disease, increasing aging population and increasing advancements in medical science, increasing government vaccination programs & initiatives etc. Apart from the significant efforts market also face some of the major challenges which include product recalls, the high cost of conjugate vaccines development and inadequate access to vaccines etc. In Europe some of the new opportunities expected to focus on therapeutic vaccines, high growth prospects in the emergent market and the use of an adjuvant in vaccines etc.
It is expected that the European conjugate vaccine market to reach US$ 8.9 billion, at a CAGR of 3.6%, by 2023. By volume term, it is estimated that this market will be reached 504.4 million units, growing at a CAGR of 3.7%. In the near future, it is predicted that the market to grow progressively owing to the rising implementation of cancer medicinal vaccines.
To know more, click on the link below:-
Related Reports:-
https://www.kenresearch.com/healthcare/pharmaceuticals/us-conjugate-vaccine-2018-2023/172477-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
